Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...
SAN FRANCISCO -- Men with advanced prostate cancer and limited metastatic recurrence lived more than twice as long without disease progression when they received metastasis-directed radioactive ...
Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...
A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ...
Impact of homologous recombination repair gene mutations on survival in metastatic castration-sensitive prostate cancer (mCSPC) from an observational database. PTEN 58 vs 48, p = 0.36 38 vs 20, p = ...
Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...
BRCA- and tumor suppressor gene mutations are associated with worse overall survival among patients receiving lutetium-177 PSMA radioligand therapy for mCRPC. Lutetium-177-PMSA radioligand therapy (Lu ...
Pooled trials show Pluvicto improves progression-free survival in advanced prostate cancer, without increasing serious adverse events. An examination of data from more than 2500 patients with advanced ...
The MarketWatch News Department was not involved in the creation of this content. -- A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results